FFP104 ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
93原発性胆汁性胆管炎3
96クローン病3

93. 原発性胆汁性胆管炎


臨床試験数 : 298 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02193360
(ClinicalTrials.gov)
May 201511/7/2014Pilot Study of FFP104 Dose Escalation in PBC SubjectsA Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)Primary Biliary CirrhosisDrug: FFP104Fast Forward PharmaceuticalsNULLRecruiting18 Years75 YearsBoth24Phase 1/Phase 2Netherlands;United Kingdom
2EUCTR2014-001638-27-GB
(EUCTR)
16/02/201511/12/2014A dose finding study of FFP104 for patients with Primary Biliary Cirrhosis (PBC)A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed with Primary Biliary Cirrhosis (PBC) - Pilot Study of FFP104 Dose Escalation in PBC Subjects Primary Biliary Cirrhosis (PBC)
MedDRA version: 19.0;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: FFP104Fast Forward Pharmaceuticals, B.V.NULLNot Recruiting Female: yes
Male: yes
24 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noNetherlands;United Kingdom
3EUCTR2014-001638-27-NL
(EUCTR)
15/10/201421/07/2014A dose finding study of FFP104 for patients with Primary Biliary Cirrhosis (PBC)A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed with Primary Biliary Cirrhosis (PBC) - Pilot Study of FFP104 Dose Escalation in PBC Subjects Primary Biliary Cirrhosis (PBC)
MedDRA version: 18.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: FFP104Fast Forward Pharmaceuticals, B.V.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2Netherlands;United Kingdom

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-001678-17-NL
(EUCTR)
14/01/201614/01/2016A Pilot Study of FFP104 in Subjects with Crohn’s DiseaseA Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects with Moderate to Severely Active Crohn’s Disease Moderate to Severely Active Crohn’s disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: FFP104Fast Forward Pharmaceuticals, B.V.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2Belgium;Netherlands
2NCT02465944
(ClinicalTrials.gov)
January 201618/5/2015A Pilot Study of FFP104 in Subjects With Crohn's DiseaseA Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's DiseaseCrohn's DiseaseDrug: FFP104;Drug: PlaceboFast Forward PharmaceuticalsNULLRecruiting18 Years75 YearsBoth24Phase 1/Phase 2Belgium;Netherlands
3EUCTR2015-001678-17-BE
(EUCTR)
01/12/201510/09/2015A Pilot Study of FFP104 in Subjects with Crohn’s DiseaseA Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects with Moderate to Severely Active Crohn’s Disease Moderate to Severely Active Crohn’s disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Code: FFP104Fast Forward Pharmaceuticals, B.V.NULLNot RecruitingFemale: yes
Male: yes
24Phase 2Belgium;Netherlands